Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 6/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 7/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465805 | 0.88 | PIK3CD (0.51) | EHMT2EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL22598590 | 0.88 | PIK3CD (0.51) | EHMT2EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL29465790 | 0.86 | PIK3CD (0.54) | EPHA2ERBB2EPHB4PIK3CDPIK3CA | |
| SCHEMBL29465791 | 0.86 | PIK3CD (0.54) | EPHA2ERBB2EPHB4PIK3CDPIK3CA | |
| SCHEMBL2453138 | 0.86 | PIK3CD (0.54) | EPHA2ERBB2EPHB4PIK3CDPIK3CA | |
| SCHEMBL665187 | 0.86 | PIK3CD (0.54) | EPHA2ERBB2EPHB4PIK3CDPIK3CA | |
| SCHEMBL28835268 | 0.85 | ERBB2 (0.49) | EHMT2EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL17179572 | 0.85 | ERBB2 (0.49) | EHMT2EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL28835269 | 0.85 | ERBB2 (0.49) | EHMT2EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL29834734 | 0.84 | PIK3CD (0.62) | EPHA2ERBB2EPHB4PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | EHMT2 4166/4885EPHA2 297/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.